SCHEMBL12436799

SCHEMBL12436799

CCN(C)C(=O)NC1CCC(C(C)=O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.36
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
HTR2A P28223 1/20 0.36
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 3/20 0.35
ADRA2A P08913 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPY5R Q15761 3/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MME P08473 1/20 0.32
FASN P49327 1/20 0.32
BCHE P06276 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722016 1.00 HTR1A (0.36) HTR1ADRD2DRD3HTR2AEPHX2
SCHEMBL23169461 0.80 PKM (0.50) EPHX2ALDH1A1ADRA2ASMN1; SMN2PKM
SCHEMBL9008707 0.77 EPHX1 (0.52) HTR1ADRD2DRD3HTR2AEPHX2
SCHEMBL18950688 0.77 DRD2 (0.47) HTR1ADRD2DRD3HTR2AALDH1A1
SCHEMBL18950691 0.77 DRD2 (0.47) HTR1ADRD2DRD3HTR2AALDH1A1
SCHEMBL12436723 0.76 MTNR1A (0.44) DRD2EPHX2ALDH1A1SMN1; SMN2KMT2A
SCHEMBL22721998 0.76 MTNR1A (0.44) DRD2EPHX2ALDH1A1SMN1; SMN2KMT2A
SCHEMBL23573400 0.74 MME (0.40) ALDH1A1KMT2ALMNACYP3A4GAA
SCHEMBL23573398 0.74 MME (0.40) ALDH1A1KMT2ALMNACYP3A4GAA
SCHEMBL24449867 0.73 DRD2 (0.40) HTR1ADRD2DRD3HTR2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B HTR1A 198/4885DRD2 135/4885DRD3 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.